These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

974 related items for PubMed ID: 17543777

  • 1. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
    Valantine H.
    J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
    [Abstract] [Full Text] [Related]

  • 2. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
    Campistol JM, Albanell J, Arns W, Boletis I, Dantal J, de Fijter JW, Mortensen SA, Neumayer HH, Øyen O, Pascual J, Pohanka E, Schena FP, Serón D, Sparacino V, Chapman JR.
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
    [Abstract] [Full Text] [Related]

  • 3. Post-transplant de novo malignancies in renal transplant recipients: the past and present.
    Kauffman HM, Cherikh WS, McBride MA, Cheng Y, Hanto DW.
    Transpl Int; 2006 Aug; 19(8):607-20. PubMed ID: 16827677
    [Abstract] [Full Text] [Related]

  • 4. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
    Rostaing L, Kamar N.
    J Nephrol; 2010 Aug; 23(2):133-42. PubMed ID: 20155724
    [Abstract] [Full Text] [Related]

  • 5. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients.
    Andrés V, Castro C, Campistol JM.
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii14-7. PubMed ID: 16815851
    [Abstract] [Full Text] [Related]

  • 6. Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions.
    Epailly E, Albanell J, Andreassen A, Bara C, Campistol JM, Delgado JF, Eisen H, Fiane AE, Mohacsi P, Schubert S, Sebbag L, Turazza FM, Valantine H, Zuckermann A, Potena L.
    Clin Transplant; 2011 Jul; 25(5):E475-86. PubMed ID: 21592231
    [Abstract] [Full Text] [Related]

  • 7. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [Abstract] [Full Text] [Related]

  • 8. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation.
    de Fijter JW.
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i23-6. PubMed ID: 17456615
    [Abstract] [Full Text] [Related]

  • 9. Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors.
    Pascual J.
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i27-35. PubMed ID: 17456616
    [Abstract] [Full Text] [Related]

  • 10. Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors.
    Campistol JM, Schena FP.
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i17-22. PubMed ID: 17456614
    [Abstract] [Full Text] [Related]

  • 11. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation.
    Zuckermann A, Manito N, Epailly E, Fiane A, Bara C, Delgado JF, Lehmkuhl H, Ross H, Eisen H, Chapman J, Valantine H.
    J Heart Lung Transplant; 2008 Feb; 27(2):141-9. PubMed ID: 18267219
    [Abstract] [Full Text] [Related]

  • 12. The impact of mTOR inhibitors on the development of malignancy.
    Geissler EK.
    Transplant Proc; 2008 Dec; 40(10 Suppl):S32-5. PubMed ID: 19100904
    [Abstract] [Full Text] [Related]

  • 13. Calcineurin inhibitors in heart transplantation.
    Keogh A.
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S202-6. PubMed ID: 15093806
    [Abstract] [Full Text] [Related]

  • 14. Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.
    Gaumann A, Schlitt HJ, Geissler EK.
    Transpl Int; 2008 Mar; 21(3):207-17. PubMed ID: 18069922
    [Abstract] [Full Text] [Related]

  • 15. Cardiac allograft vasculopathy after heart transplantation: risk factors and management.
    Valantine H.
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S187-93. PubMed ID: 15093804
    [Abstract] [Full Text] [Related]

  • 16. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center.
    Mihalov ML, Gattuso P, Abraham K, Holmes EW, Reddy V.
    Clin Transplant; 1996 Jun; 10(3):248-55. PubMed ID: 8826661
    [Abstract] [Full Text] [Related]

  • 17. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.
    Kahan BD.
    Transplant Proc; 2008 Dec; 40(10 Suppl):S17-20. PubMed ID: 19100899
    [Abstract] [Full Text] [Related]

  • 18. Can immunosuppressive strategies be used to reduce cancer risk in renal transplant patients?
    Geissler EK.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S32-5. PubMed ID: 21095449
    [Abstract] [Full Text] [Related]

  • 19. Cancers after renal transplantation.
    Wong G, Chapman JR.
    Transplant Rev (Orlando); 2008 Apr; 22(2):141-9. PubMed ID: 18631867
    [Abstract] [Full Text] [Related]

  • 20. The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy.
    Klintmalm GB, Saab S, Hong JC, Nashan B.
    Clin Transplant; 2014 Jun; 28(6):635-48. PubMed ID: 24628264
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.